Medtronic plc added a second U.S. FDA pulsed field ablation (PFA) device approval to its scorecard with the agency’s ...

Affera combines mapping technology with a catheter capable of performing radiofrequency and pulsed field ablation.

Less than a year after obtaining an FDA approval for its first foray into pulsed field ablation, Medtronic has done it again.

This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.

Analyst Travis Steed from Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report) and keeping the price ...

Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today. Michael Matson’s rating is ...

Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.

Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...

The FDA approved an early feasibility study of Medtronic’s Affera mapping and ablation system and Sphere-9 catheter in ...

The study aims to assess the Catheter and Affera system in patients who have ventricular tachycardia (VT) due to scarring ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...

Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...